INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,415,181 | -5.7% | 27,168 | +14.6% | 0.13% | -4.4% |
Q2 2023 | $1,500,937 | +17.2% | 23,704 | +0.2% | 0.14% | +7.1% |
Q1 2023 | $1,280,756 | +3.0% | 23,652 | +0.6% | 0.13% | -2.3% |
Q4 2022 | $1,243,938 | +132.5% | 23,506 | +104.6% | 0.13% | +134.5% |
Q3 2022 | $535,000 | -7.4% | 11,490 | +13.5% | 0.06% | -5.2% |
Q2 2022 | $578,000 | – | 10,123 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |